DAWN Day One Biopharmaceuticals Inc
Price (delayed)
$8.95
Market cap
$907.12M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.02
Enterprise value
$784.76M
Highlights
The company's EPS has surged by 57% YoY
DAWN's revenue is up by 29% from the previous quarter
DAWN's net income is up by 49% year-on-year but it is down by 13% since the previous quarter
The company's equity rose by 45% YoY but it fell by 9% QoQ
The quick ratio has contracted by 48% from the previous quarter and by 40% YoY
Key stats
What are the main financial stats of DAWN
Market
Valuations
Earnings
Shares outstanding
101.35M
Market cap
$907.12M
Enterprise value
$784.76M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.8
Price to sales (P/S)
6.36
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.98
Revenue
$131.16M
Gross profit
$125.88M
Operating income
-$217.27M
Net income
-$95.5M
EBIT
-$88.35M
EBITDA
-$86.32M
Free cash flow
$27.72M
Per share
Balance sheet
Liquidity
EPS
-$1.02
EPS diluted
-$1.02
Free cash flow per share
$0.3
Book value per share
$4.99
Revenue per share
$1.41
TBVPS
$6.08
Total assets
$582.79M
Total liabilities
$80.04M
Debt
$2.6M
Equity
$502.75M
Working capital
$488.88M
Debt to equity
0.01
Current ratio
7.66
Quick ratio
7.43
Net debt/EBITDA
1.42
Margins
Efficiency
Dividend
EBITDA margin
-65.8%
Gross margin
96%
Net margin
-72.8%
Operating margin
-165.7%
Return on assets
-20%
Return on equity
-23%
Return on invested capital
-61.6%
Return on capital employed
-17.3%
Return on sales
-67.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DAWN stock price
How has the Day One Biopharmaceuticals stock price performed over time
Intraday
3.35%
1 week
-7.73%
1 month
-26.22%
1 year
-39.24%
YTD
-29.36%
QTD
-29.36%
Financial performance
How have Day One Biopharmaceuticals's revenue and profit performed over time
Revenue
$131.16M
Gross profit
$125.88M
Operating income
-$217.27M
Net income
-$95.5M
Gross margin
96%
Net margin
-72.8%
DAWN's net income is up by 49% year-on-year but it is down by 13% since the previous quarter
DAWN's revenue is up by 29% from the previous quarter
Day One Biopharmaceuticals's gross profit has increased by 26% QoQ
Day One Biopharmaceuticals's operating margin has increased by 20% QoQ
Growth
What is Day One Biopharmaceuticals's growth rate over time
Valuation
What is Day One Biopharmaceuticals stock price valuation
P/E
N/A
P/B
1.8
P/S
6.36
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.98
The company's EPS has surged by 57% YoY
The stock's P/B is 49% less than its last 4 quarters average of 3.4
The company's equity rose by 45% YoY but it fell by 9% QoQ
DAWN's revenue is up by 29% from the previous quarter
Efficiency
How efficient is Day One Biopharmaceuticals business performance
The ROA has soared by 59% year-on-year
Day One Biopharmaceuticals's ROE has soared by 56% YoY but it has decreased by 2.7% from the previous quarter
The ROIC has grown by 41% from the previous quarter and by 38% YoY
The company's return on sales rose by 18% QoQ
Dividends
What is DAWN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DAWN.
Financial health
How did Day One Biopharmaceuticals financials performed over time
Day One Biopharmaceuticals's total liabilities has surged by 171% YoY and by 77% QoQ
DAWN's total assets has soared by 55% year-on-year but it is down by 3% since the previous quarter
The debt is 99% smaller than the equity
The company's equity rose by 45% YoY but it fell by 9% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.